

Morgan Stanley

Research
North America

Managing the Food/Feed/Finance Intersection

*2008 USDA Outlook Conference
Washington, DC*

Vincent Andrews

Vice President

Agricultural Products & Packaged Food

February 21, 2008

Morgan Stanley does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. [Customers of Morgan Stanley in the U.S. can receive independent, third-party research on the company covered in this report, at no cost to them, where such research is available. Customers can access this independent research at www.morganstanley.com/equityresearch or can call 800-624-2063 to request a copy of this research.]

For analyst certification and other important disclosures, refer to Disclosure Section located at the end of this report.

What is my vantage point?

- Entire value chain from Monsanto to ADM to Kraft
 - *Seeds to ethanol to macaroni and cheese*
- The full panoply of investor *interest* and *concern* as it relates to:
 - *Renewable fuels;*
 - *Higher commodity prices;*
 - *Global food price inflation; and*
 - *The potential for second generation biofuels*

Morgan Stanley is currently acting as financial advisor to VeraSun Energy Corp. ("VeraSun") with respect to its announced proposed merger with US BioEnergy Corp. ("US BioEnergy"), as announced on November 29, 2007. The proposed transaction is subject to the consent of VeraSun and US BioEnergy shareholders, anti-trust regulatory clearance, and other customary closing conditions. This report and the information provided herein is not intended to (i) provide voting advice, (ii) serve as an endorsement of the proposed transaction, or (iii) result in the procurement, withholding or revocation of a proxy or any other action by a security holder. Verasun has agreed to pay fees to Morgan Stanley for its financial advice, including transaction fees that are subject to the consummation of the proposed transaction. Please refer to the notes at the end of the report.

What am I going to talk about?

- Where is investor capital now?
 - *Front end of the value chain*
- Where is investor capital going?
 - *Looking to unlock bottlenecks*
- What are the key investor concerns?
 - *Volatility and uncertainty around politics and economics*

Where is investor capital now?

- *The Good News*
 - Six ethanol companies IPOed from 2005 to 2007
 - The combined US market capitalization of Agriculture related companies is around \$265 billion, compared to around \$140 billion one year ago

Agriculture Market Capitalization



Source: Morgan Stanley Research, Factset

- (1) VeraSun Energy Corp. (VSE) IPOed June 2006; US BioEnergy Corp. (USB) IPOed December 2006; Xethanol Corp. (XNL) IPOed March 2005; Aventine Renewable Energy (AVR) IPOed July 2006; Biofuel Energy Corp. (BIOF) IPOed June 2007; Pacific Ethanol, Inc. (PEIX) IPOed March 2005;
- (2) Agriculture Market Capitalization includes: Pilgrim's Pride (PPC), Sanderson Farms (SAFM), Smithfield Foods (SFD), Tyson Foods (TSN), Deere & Co. (DE), Agrium Inc. (AGU), Andersons Inc. (ANDE), Mosaic Co. (MOS), Potash Corp. (POT), Terra Industries (TRA), Bunge Ltd. (BG), Corn Products International (CPO), Archer Daniels Midland (ADM), Monsanto Co. (MON), VeraSun Energy Corp. (VSE), US BioEnergy Corp. (USB), Xethanol Corp. (XNL), Aventine Renewable Energy (AVR), Biofuel Energy Corp. (BIOF), Pacific Ethanol, Inc. (PEIX)

Where is investor capital now?

- *The Bad News*

- Ethanol market capitalizations peaked at \$3.5 billion and now stand closer to \$2 billion
- We have not seen a new renewable fuels IPO since June 2007

Ethanol Market Capitalization




Source: Morgan Stanley Research, Factset

Where is investor capital now?

- *The Reality: Investors have been better off at the front end of the value chain*
- Due to higher commodity prices farmers have more money to spend. Companies selling inputs to farmers have performed extremely well (Bunge, Deere, Monsanto, Mosaic, Potash, etc.)

Ethanol Producers vs. Agriculture Input Providers




Note: Above chart compares market capitalization indexed to July 1, 2006

Source: Morgan Stanley Research, Factset

Where is investor capital now?

- *The Reality: Investors have been better off at the front end of the value chain*
- Total revenue pie available from US corn and soybean production: ~\$55 billion during the 2006 marketing year to \$79 billion during the 2007 marketing year
- Holding today's commodity prices and last year's yields constant the revenue pie will grow again to ~\$100 billion during the 2008 marketing year

Corn and Soybean Revenue Pie




Source: Morgan Stanley Research Estimates, USDA

Where is investor capital now?

- *The Reality: Investors have been better off at the front end of the value chain*
- Total revenue pie available from US ethanol production: **\$12.3 billion during 2006, \$12.4 billion during 2007 (1% growth in revenue, but 20% growth in volume)**

Ethanol Revenue Pie



Source: Morgan Stanley Research Estimates, Bloomberg, Renewable Fuels Association

Where is investor capital going? To unlock *Bottlenecks*

- *The ideal:*
 - Barriers to entry;
 - Sustainable competitive advantages;
 - High margins; and
 - Predictable and growing cash flow
- Companies with the above characteristics tend to have the capability to unlock bottlenecks
- *Companies without them tend to be stuck in the bottleneck*

What are the key “bottlenecks” today?

1. Supply of arable land
2. Disparity in global crop yields
3. US Ethanol blending: Either 10% or 85%. What about in-between?
4. Second generation biofuels: What? Where? When? How?

1. We simply do not have enough land

- To meet demand from both emerging markets for protein and developed markets for biofuels
 - *Some land in CRP, Brazil, Ukraine, etc. but it will not be enough over time*
- Can we produce enough corn to satisfy RFS II?
 - *At what price?*
 - *With what collateral consequences?*
- Can Brazil expand soybean acreage enough to allow the US to grow more corn?
 - *Does that require a secularly higher soybean price (i.e., logistics costs, USD/Brazilian Real, etc.)?*

2. Massive disparity in global yields; the opportunity to create “virtual” acres

- US Corn acres more productive; Rest of the World must improve
 - *US corn yield: ~153 bushels per acre; Ex-US weighted average corn yield: ~70 bushels per acre*
 - *If the rest of the world was at yield parity with the US, ~75 million virtual acres would be created*
- 4 pieces of biotechnology on the farm today; 30+ to come
 - *Average US corn yields could potentially get to ~200 bushels per acre*
 - *This would amount to an additional 29 million “virtual” acres at current US yield and planted corn acreage;*
- We believe that increased biotechnology use outside of the US is crucial.
 - *Brazil just approved biotech corn*
 - *The EU remains resistant*
 - *What about China?*

(1) “Rest of world” virtual acres is calculated using total foreign acres deemed applicable for biotech (~65 million acres in the EU, Brazil, Argentina, and India).

3. There is a lot of room between E10 and E85

- Blends above 10% but less than 30% would provide a substantial buffer for production/capacity build out
 - *Some work already being done on this (Department of Energy; State of Minnesota; language in both the farm and the energy bills)*
 - *Brazil already using higher blends*
 - *Flex fuel cars = 85% blend*
 - *Non flex-fuel cars warranted up to a 10% blend of ethanol*

4. Tell me what second generation biofuels are and how soon we will have them?

- Ask ten different people, get ten different answers to:
 - *What feedstock will be used?*
 - *Where will it be grown?*
 - *Is it already being grown in size?*
 - *How will it get from the farm to the end market?*
 - *What will the logistics costs be?*
 - *Can we use existing ethanol plants?*
 - *If so, are they properly located?*
 - *Do we need new plants anyway?*
 - *Will displacement be an issue? How long will it take?*
 - *How much government support will be necessary?*


What are the key “investor concerns” today?

- 1. Political support
- 2. Are we doing the right thing?
- 3. Global competition (i.e., the import tariff)
- 4. Rational development of both current and future biofuels

1. Political support

- The need/sustainability of political support (legislation) and subsidies (finance).
 - *What happens to my investment if political support dissipates?*
 - The blenders' tax credit
 - *Am I investing in an industry or an administration?*
 - The investor debate has shifted from: *Will the RFS be increased?* to *When will the RFS be repealed?*


Renewable Fuels Standard



Drilling down on the blenders' tax credit

- \$0.51 per gallon ethanol blenders tax credit has not been optimal as it has only aided the investor argument that the ethanol industry cannot stand on its own
 - To date, the constituent who did not need the tax credit has largely enjoyed it anyway creating supply / demand imbalances + price / profitability volatilities
 - When supply was tight Ethanol manufacturers received the tax credit in the ethanol price they were paid
 - With supply/demand out of balance, the blender is realizing the entire tax credit in the price that he is paying
 - In hindsight, subsidy needed to be directly relevant to plant construction, and blending infrastructure
 - *Investors want either a free market system or subsidies that work*

Ethanol Prices vs. RBOB



Source: Morgan Stanley Research, Bloomberg

2. Are we doing the right thing?

- Getting past the ideology to analyze the merits of the underlying investment
 - *Does ethanol have a positive energy balance?*
 - *Should we be turning corn into gasoline?*
 - *The potential consequences of higher soft commodity prices*
 - US consumers (higher prices)
 - Developing economies (help or hurt poverty)
 - What is the true cost of the renewable fuels program?

3. Global competition

- What's the sustainability of the \$0.54 per gallon import tariff and the \$0.51 blender's tax credit?
- Can the industry survive without subsidies and tariffs?
- Does it make more sense for Brazil to make ethanol with sugar?

4. Rational development of both the current and future industry?

- **There is currently 7.7 billion gallons of ethanol capacity. RFS II gives us a roadmap to 15 billion by 2015**
- Will gross corn costs and byproduct credits (DDGS) allow for profitability?
- Why will the build out of second generation biofuels be any different than first generation biofuels?
- Will second generation biofuels render first generation biofuels obsolete?

Conclusion / Questions

- **Where is investor capital now?**
 - Front end of the value chain: *inputs rather than outputs*
- **Where is investor capital going?**
 - Looking to unlock bottlenecks: Supply of land; increasing yields; intermediate ethanol blends; and second generation biofuels
- **What keeps investors on the sidelines?**
 - Volatility and uncertainty surrounding: Political support; are we doing the right thing arguments; potential threat of global competition; and rational development of both current and future biofuels

Disclosure Section



Morgan Stanley ModelWare is a proprietary analytic framework that helps clients uncover value, adjusting for distortions and ambiguities created by local accounting regulations. For example, ModelWare EPS adjusts for one-time events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis. ModelWare also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings.

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. Incorporated, and/or Morgan Stanley Dean Witter C.T.V.M. S.A. and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Equity Research Management), New York, NY, 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Vincent Andrews.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictolicies.

Important US Regulatory Disclosures on Subject Companies

As of January 31, 2008, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Archer Daniels Midland, Corn Products International Inc., Monsanto Company.

As of January 31, 2008, Morgan Stanley held a net long or short position of US\$1 million or more of the debt securities of the following issuers covered in Morgan Stanley Research (including where guarantor of the securities): Archer Daniels Midland, Bunge Ltd., Monsanto Company, Smithfield Foods, Tyson Foods.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering of securities of Bunge Ltd., Corn Products International Inc., Smithfield Foods.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Bunge Ltd., Corn Products International Inc., Smithfield Foods.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Bunge Ltd., Corn Products International Inc., Monsanto Company, Smithfield Foods.

Within the last 12 months, Morgan Stanley & Co. Incorporated has received compensation for products and services other than investment banking services from Archer Daniels Midland, Bunge Ltd., Corn Products International Inc..

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Bunge Ltd., Corn Products International Inc., Monsanto Company, Smithfield Foods.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Archer Daniels Midland, Bunge Ltd., Corn Products International Inc..

The research analysts, strategists, or research associates principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

Disclosure Section

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight and Underweight are not the equivalent of Buy, Hold and Sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of January 31, 2008)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight to hold and Underweight to sell recommendations, respectively.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)		
	Count	% of Total	Count	% of Total IBC	% of Rating Category
Overweight/Buy	1048	44%	333	45%	32%
Equal-weight/Hold	986	41%	308	42%	31%
Underweight/Sell	346	15%	98	13%	28%
Total	2,380		739		

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley or an affiliate received investment banking compensation in the last 12 months.

Disclosure Section

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley or an affiliate received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

More volatile (V). We estimate that this stock has more than a 25% chance of a price move (up or down) of more than 25% in a month, based on a quantitative assessment of historical data, or in the analyst's view, it is likely to become materially more volatile over the next 1-12 months compared with the past three years. Stocks with less than one year of trading history are automatically rated as more volatile (unless otherwise noted). We note that securities that we do not currently consider "more volatile" can still perform in that manner.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

Other Important Disclosures

Morgan Stanley produces a research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in this or other research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

For a discussion, if applicable, of the valuation methods used to determine the price targets included in this summary and the risks related to achieving these targets, please refer to the latest relevant published research on these stocks.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The securities/instruments discussed in Morgan Stanley Research may not be suitable for all investors. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities or derivatives of securities of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities or derivatives of securities of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

Morgan Stanley and its affiliate companies do business that relates to companies/instruments covered in Morgan Stanley Research, including market making and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis.

With the exception of information regarding Morgan Stanley, research prepared by Morgan Stanley Research personnel are based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel conduct site visits from time to time but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits.

The value of and income from your investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in your securities transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. Unless otherwise stated, the cover page provides the closing price on the primary exchange for the subject company's securities/instruments.

Disclosure Section

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Morgan Stanley Research is disseminated in Japan by Morgan Stanley Japan Securities Co., Ltd.; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents); in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore, which accepts responsibility for its contents; in Australia by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services licence No. 233742, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of Morgan Stanley Research in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. Incorporated, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized and regulated by Financial Services Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Private U.K. investors should obtain the advice of their Morgan Stanley & Co. International plc representative about the investments concerned. In Australia, Morgan Stanley Research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and FirstRand Investment Holdings Limited, which is wholly owned by FirstRand Limited.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at wholesale customers only, as defined by the DFSA. This research will only be made available to a wholesale customer who we are satisfied meets the regulatory criteria to be a client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion hereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

The Americas

1585 Broadway
New York, NY 10036-8293
United States
Tel: +1 (1)212 761 4000

Europe

25 Cabot Square, Canary Wharf
London E14 4QA
United Kingdom
Tel: +44 (0)20 7425 8000

Japan

4-20-3 Ebisu, Shibuya-ku
Tokyo 150-6008
Japan
Tel: +81 (0) 3 5424 5000

Asia/Pacific

Three Exchange Square
Central
Hong Kong
Tel: +852 2848 5200